Analystreport

Corvus Pharmaceuticals (NASDAQ:CRVS) was upgraded by analysts at Barclays PLC to a "strong-buy" rating.

Corvus Pharmaceuticals, Inc.  (CRVS) 
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corvuspharma.com